FDA Announces Recall of Drugs Containing Valsartan | Bradley, Drendel & Jeanney
(775) 525-9164
Call Us Today
(800) 330-1101
Free Consultation

FDA Announces Recall of Drugs Containing Valsartan

On July 13, 2018 the FDA announced a voluntary recall of several medicines containing valsartan, used to treat high blood pressure and heart failure. The recall is due to an impurity, N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen. 

You can learn more information about this recall here: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM613532.htm

Our attorneys at Bradley, Drendel & Jeanney are currently representing several individuals who suffered injury from taking the contaminated medications containing valsartan. Our law firm is actively and aggressively investigating this matter in order to provide those affected with accurate, timely information. If you believe you or a loved one has been injured by taking a contaminated medication containing valsartan, please feel free to contact our firm.

No Comments

Leave a comment
Comment Information
  • Million Dollar Advocates Forum
  • American Board Of Trial Advocates
  • NJA - Nevada Justice Association
  • Distinguished TM AV Lexis Nexis Martindale Hubbell Peer Review Rated For Ethical Standards And Legal Ability
  • EST. 1972 7 The Inner Circle of Advocates
  • Super Lawyers
  • American College Of Trial Lawyers
  • American Association For Justice

Contact Us Today About Your Claim

After an accident, our personal injury attorneys in Reno will fight your legal battles so you can focus on healing. Contact us online today at 775-525-9164 or fill out the form below. We are ready to help you obtain the compensation you deserve. Free consultations No fee unless we win your case

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy